Catalent Biologics Collaborates with Swiss Biotech to Develop Achondroplasia Therapy
CDMO Catalent to Commercially Manufacture Lexicon’s Recently-Approved Drug
Catalent to Develop Softgel Capsules for Jupiter Orphan Therapeutics
Catalent to Provide Fill & Finish Services for Samsung Bioepis’ Biosimilar
SOMERSET, N.J. — Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that it is to provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel (etanercept), on behalf of the Korea-based biopharmaceutical company Samsung Bioepis Co.,…
